JPH09508912A - 性ステロイドを含有する経皮治療系 - Google Patents
性ステロイドを含有する経皮治療系Info
- Publication number
- JPH09508912A JPH09508912A JP7521561A JP52156195A JPH09508912A JP H09508912 A JPH09508912 A JP H09508912A JP 7521561 A JP7521561 A JP 7521561A JP 52156195 A JP52156195 A JP 52156195A JP H09508912 A JPH09508912 A JP H09508912A
- Authority
- JP
- Japan
- Prior art keywords
- transdermal
- estrogen
- sheet
- gestagen
- dimethylisosorbide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
- A61K9/7061—Polyacrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
- A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
- A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/34—Gestagens
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Reproductive Health (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.性ステロイド及び場合により浸透促進剤及び結晶化抑制剤を含有する経皮 治療系において、これが、作用物質含有非流動性ゲル相又は3−ケト−デソゲス トレルを含有する系の他に、ジメチルイソソルビドを含有することを特徴とする 、性ステロイド及び場合により浸透促進剤及び結晶化抑制剤を含有する経皮治療 系。 2.性ステロイドとして、ゲスタゲン及び/又はエストロゲンを含有する、請 求項1に記載の経皮治療系。 3.ゲスタゲンとして、ゲストーデン、レボノルゲストレル、デソゲストレル 、ノルエチステロン又はノルエチステロンアセテートを含有する、請求項2に記 載の経皮治療系。 4.エストロゲンとして、エストラジオール、エストリオール、17α−エチ ニルエストラジオール、メストラノール、14α,17α−エタノエストラ−1 ,3,5(10)−トリエン−3,17β−ジオール、14α,17α−エタノ エストラ−1,3,5(10)−トリエン−3,16α,17β−トリオール又 はこれらの化合物のエステルを含有する、請求項2に記載の経皮治療系。 5.全作用物質相に対して、ジメチルイソソルビド 1〜40重量%を含有する、請求項1から5のいずれかに記載の経皮治療系。 6.a)非透過性上被層、 1〜3つの、上被層に付着し、ゲスタゲン及び/又はエストロゲン及びジメチ ルイソソルビド及び場合により、浸透促進剤及び結晶化抑制剤を含有し、皮膚圧 感接着剤で覆われているか又は囲まれたマトリックス層、剥離可能な保護層又は b)所望の場合には浸透促進剤を含有する圧感接着剤を備えた上被、 1〜2つの、圧感接着剤のふち部を覆わず、非透過性被覆により圧感接着剤に 固定され、ゲスタゲン及び/又はエストロゲン及びジメチルイソソルビド及び場 合により浸透促進剤及び結晶化抑制剤を含有するマトリックス層及び剥離可能な 保護層 からなる、請求項1から5のいずれかに記載の経皮治療系。 7.1つの作用物質含有マトリックス層を含有する、請求項6に記載の経皮投 与のための薬剤。 8.2又は3つの作用物質含有マトリックス層を含有する、請求項6に記載の 経皮投与のための薬剤。 9.作用物質含有マトリックス層が、種々異なる作用物質を含有する、請求項 8に記載の経皮投与のための薬剤。 10.請求項1から9のいずれかに記載の経皮投与 のためのエストロゲン不含の薬剤を、経皮避妊、子宮内膜症の治療、ゲスタゲン 依存性腫瘍の治療及び月経前期症候群の治療のために使用すること。 11.請求項1から9のいずれかに記載の経皮投与のための薬剤を、場合によ り、エストロゲン含有剤と組み合わせて、更年期障害の治療、骨粗鬆症の予防、 周期制御、周期安定及び経皮避妊のために使用すること。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE4405898A DE4405898A1 (de) | 1994-02-18 | 1994-02-18 | Transdermale therapeutische Systeme enthaltend Sexualsteroide |
DE4405898.5 | 1994-02-18 | ||
PCT/EP1995/000483 WO1995022322A1 (de) | 1994-02-18 | 1995-02-09 | Transdermale therapeutische systeme enthaltend sexualsteroide |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH09508912A true JPH09508912A (ja) | 1997-09-09 |
Family
ID=6511044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP7521561A Pending JPH09508912A (ja) | 1994-02-18 | 1995-02-09 | 性ステロイドを含有する経皮治療系 |
Country Status (17)
Country | Link |
---|---|
US (1) | US5904931A (ja) |
EP (1) | EP0744944B1 (ja) |
JP (1) | JPH09508912A (ja) |
KR (1) | KR100392435B1 (ja) |
AT (1) | ATE186213T1 (ja) |
AU (1) | AU1706695A (ja) |
CA (1) | CA2183543C (ja) |
DE (2) | DE4405898A1 (ja) |
DK (1) | DK0744944T3 (ja) |
ES (1) | ES2140658T3 (ja) |
GR (1) | GR3032512T3 (ja) |
HU (1) | HUT74876A (ja) |
NO (1) | NO313813B1 (ja) |
NZ (1) | NZ279820A (ja) |
PT (1) | PT744944E (ja) |
RU (1) | RU2154455C2 (ja) |
WO (1) | WO1995022322A1 (ja) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002536403A (ja) * | 1999-02-10 | 2002-10-29 | イエナフアルム ゲーエムベーハー ウント ツェーオー. カーゲー | 経皮系のための作用物質含有ラミネート |
JP2004525872A (ja) * | 2000-12-21 | 2004-08-26 | シエーリング アクチエンゲゼルシャフト | 強力なゲスターゲンを含有する経皮系 |
JP2012533598A (ja) * | 2009-07-21 | 2012-12-27 | ノバルティス アーゲー | 医薬組成物 |
JP2018199701A (ja) * | 2011-05-15 | 2018-12-20 | エーセラス ファーマシューティカルズ コーポレーション | 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用 |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19635883A1 (de) * | 1996-09-04 | 1998-03-05 | Lohmann Therapie Syst Lts | Transdermales therapeutisches System mit einer Östriol enthaltenden Wirkstoffkombination |
DE19701949A1 (de) * | 1997-01-13 | 1998-07-16 | Jenapharm Gmbh | Transdermales therapeutisches System |
DE19739916C2 (de) * | 1997-09-11 | 2001-09-13 | Hesch Rolf Dieter | Verwendung einer Kombination aus einem Gestagen und einem Estrogen zur kontinuierlichen Ovulationshemmung und ggf. gleichzeitigen Behandlung und/oder Prophylaxe von Tumoren der Brustdrüsen |
GB9720470D0 (en) | 1997-09-25 | 1997-11-26 | Ethical Pharmaceuticals South | Inhibition of crystallization in transdermal devices |
FR2774595A1 (fr) * | 1998-02-06 | 1999-08-13 | Rech D Innovation Et De Dev Ce | Emulsion pour l'administration transdermique de steroides |
DE19827732A1 (de) * | 1998-06-22 | 1999-12-23 | Rottapharm Bv | Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie |
DE19828273B4 (de) * | 1998-06-25 | 2005-02-24 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren |
CA2331264C (en) * | 1999-01-14 | 2008-09-23 | Noven Pharmaceuticals, Inc. | Compositions and methods for drug delivery |
US20030170195A1 (en) * | 2000-01-10 | 2003-09-11 | Noven Pharmaceuticals, Inc. | Compositions and methods for drug delivery |
US6846496B1 (en) | 1999-10-15 | 2005-01-25 | Orion Corporation | Treatment of osteoporosis |
US7384650B2 (en) * | 1999-11-24 | 2008-06-10 | Agile Therapeutics, Inc. | Skin permeation enhancement composition for transdermal hormone delivery system |
US20020004065A1 (en) | 2000-01-20 | 2002-01-10 | David Kanios | Compositions and methods to effect the release profile in the transdermal administration of active agents |
DE10025971B4 (de) * | 2000-05-25 | 2004-09-02 | Lts Lohmann Therapie-Systeme Ag | Transdermales therapeutisches System in Plasterform mit verminderter Tendenz zur Wirkstoffkristallisation und seine Verwendung |
DE10033853A1 (de) * | 2000-07-12 | 2002-01-31 | Hexal Ag | Transdermales therapeutisches System mit hochdispersem Siliziumdioxid |
AU8206401A (en) | 2000-08-03 | 2002-02-18 | Antares Pharma Ipl Ag | Novel composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels |
US8980290B2 (en) | 2000-08-03 | 2015-03-17 | Antares Pharma Ipl Ag | Transdermal compositions for anticholinergic agents |
US7198801B2 (en) * | 2000-08-03 | 2007-04-03 | Antares Pharma Ipl Ag | Formulations for transdermal or transmucosal application |
US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
US20040198706A1 (en) * | 2003-03-11 | 2004-10-07 | Carrara Dario Norberto R. | Methods and formulations for transdermal or transmucosal application of active agents |
SE0102152L (sv) * | 2001-06-18 | 2002-12-19 | Sca Hygiene Prod Ab | Ny produkt |
DE10211832A1 (de) * | 2002-03-16 | 2003-10-02 | Lohmann Therapie Syst Lts | Hormonhaltiges transdermales therapeutisches System mit einem Wirkstoffreservoir auf der Basis von Vinylacetat-Vinylpyrrolidon-Copolymer mit verbesserter Kohäsion |
EP1594483B1 (de) * | 2003-02-21 | 2006-07-19 | Schering AG | Uv-stabiles transdermales pflaster |
US20050042182A1 (en) * | 2003-08-13 | 2005-02-24 | Moshe Arkin | Topical compositions of urea |
US20050036953A1 (en) * | 2003-08-13 | 2005-02-17 | Moshe Arkin | Topical compositions of ammonium lactate |
US20050037040A1 (en) * | 2003-08-13 | 2005-02-17 | Moshe Arkin | Topical compositions of urea and ammonium lactate |
US20050042268A1 (en) * | 2003-07-16 | 2005-02-24 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050020552A1 (en) * | 2003-07-16 | 2005-01-27 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
US20050025833A1 (en) * | 2003-07-16 | 2005-02-03 | Chaim Aschkenasy | Pharmaceutical composition and method for transdermal drug delivery |
PL1670433T3 (pl) | 2003-10-10 | 2013-03-29 | Ferring Bv | Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze |
RU2356580C2 (ru) * | 2003-10-28 | 2009-05-27 | Новен Фармасьютикалз, Инк | Композиции и способы, обеспечивающие контролируемую потерю лекарственных средств и доставку в системах трансдермальной доставки лекарственных средств |
EA011160B1 (ru) * | 2003-12-12 | 2009-02-27 | Шеринг Акциенгезельшафт | Композиция для трансдермальной доставки гормонов без необходимости использования агентов, усиливающих проникновение, и ее применения |
UA89766C2 (en) | 2003-12-12 | 2010-03-10 | Байер Шеринг Фарма Акциенгезельшафт | Transdermal delivery system of gestodene |
US8668925B2 (en) | 2003-12-12 | 2014-03-11 | Bayer Intellectual Property Gmbh | Transdermal delivery of hormones without the need of penetration enhancers |
US9205062B2 (en) * | 2004-03-09 | 2015-12-08 | Mylan Pharmaceuticals, Inc. | Transdermal systems containing multilayer adhesive matrices to modify drug delivery |
US20070231373A1 (en) * | 2004-04-28 | 2007-10-04 | Hunter-Fleming Limited | Transdermal Steriod for Formulation |
US7425340B2 (en) * | 2004-05-07 | 2008-09-16 | Antares Pharma Ipl Ag | Permeation enhancing compositions for anticholinergic agents |
WO2006034147A2 (en) * | 2004-09-16 | 2006-03-30 | Abraxis Bioscience, Inc. | Compositions and methods for the preparation and administration of poorly water soluble drugs |
US20060078602A1 (en) | 2004-10-08 | 2006-04-13 | Noven Pharmaceuticals, Inc. | Device for transdermal administration of drugs including acrylic polymers |
WO2006041907A2 (en) | 2004-10-08 | 2006-04-20 | Noven Pharmaceuticals, Inc. | Transdermal delivery of estradiol |
US8962013B2 (en) * | 2005-05-02 | 2015-02-24 | Bayer Intellectual Property Gmbh | Multi-layered transdermal system with triazine UV absorber |
WO2006125642A1 (en) * | 2005-05-27 | 2006-11-30 | Antares Pharma Ipl Ag | Methods and apparatus for transdermal or transmucosal application of testosterone |
DE102005050729A1 (de) * | 2005-10-19 | 2007-04-26 | Schering Ag | Verfahren zur präventiven bedarfsweisen hormonalen Kontrazeption |
CA2646667C (en) * | 2006-04-21 | 2014-03-11 | Antares Pharma Ipl Ag | Methods of treating hot flashes with formulations for transdermal or transmucosal application |
WO2008067991A2 (en) * | 2006-12-08 | 2008-06-12 | Antares Pharma Ipl Ag | Skin-friendly drug complexes for transdermal administration |
WO2008136699A1 (fr) * | 2007-05-04 | 2008-11-13 | Igor Alexandrovich Bazikov | Patch transdermique à microcapsules et procédé de fabrication correspondant |
PL2500062T3 (pl) | 2007-11-13 | 2015-12-31 | Curadis Gmbh | Steroidy C-19 do określonych zastosowań terapeutycznych |
ES2574933T3 (es) | 2007-11-13 | 2016-06-23 | Athenion Ag | Esteroides de C-19 para usos cosméticos |
US8231906B2 (en) | 2008-07-10 | 2012-07-31 | Noven Pharmaceuticals, Inc. | Transdermal estrogen device and delivery |
AU2010237120B8 (en) | 2009-04-14 | 2015-11-26 | Laboratoire Hra-Pharma | Method for on-demand contraception |
US20120129825A1 (en) | 2009-04-14 | 2012-05-24 | Andre Ulmann | Method for on-demand contraception using levonorgestrel or norgestrel |
GB0919210D0 (en) * | 2009-11-03 | 2009-12-16 | Syntopix Ltd | Formulations |
US8563031B2 (en) * | 2010-05-27 | 2013-10-22 | Absize, Inc. | Piroxicam-containing matrix patches and methods for the topical treatment of acute and chronic pain and inflammation therewith |
DE102010040299A1 (de) | 2010-09-06 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner) |
CN103189064B (zh) | 2010-09-06 | 2015-08-12 | 拜耳知识产权有限责任公司 | 具有高药物释放的低剂量透皮贴剂 |
DK2755473T3 (en) * | 2011-09-12 | 2019-03-11 | Merial Inc | PARACITICIDE COMPOSITIONS CONTAINING AN ISOXAZOLINE ACTIVE SUBSTANCE, PROCEDURES AND APPLICATIONS THEREOF |
US9301920B2 (en) | 2012-06-18 | 2016-04-05 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
PT2782584T (pt) | 2011-11-23 | 2021-09-02 | Therapeuticsmd Inc | Preparações e terapias de substituição para hormonoterapias naturais combinadas |
US10806740B2 (en) | 2012-06-18 | 2020-10-20 | Therapeuticsmd, Inc. | Natural combination hormone replacement formulations and therapies |
US20150196640A1 (en) | 2012-06-18 | 2015-07-16 | Therapeuticsmd, Inc. | Progesterone formulations having a desirable pk profile |
US20130338122A1 (en) | 2012-06-18 | 2013-12-19 | Therapeuticsmd, Inc. | Transdermal hormone replacement therapies |
US10806697B2 (en) | 2012-12-21 | 2020-10-20 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10537581B2 (en) | 2012-12-21 | 2020-01-21 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US9180091B2 (en) | 2012-12-21 | 2015-11-10 | Therapeuticsmd, Inc. | Soluble estradiol capsule for vaginal insertion |
US10471072B2 (en) | 2012-12-21 | 2019-11-12 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11246875B2 (en) | 2012-12-21 | 2022-02-15 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US11266661B2 (en) | 2012-12-21 | 2022-03-08 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
US10568891B2 (en) | 2012-12-21 | 2020-02-25 | Therapeuticsmd, Inc. | Vaginal inserted estradiol pharmaceutical compositions and methods |
EP3010545A2 (en) * | 2013-06-20 | 2016-04-27 | Mylan Technologies, Inc. | Storage stable transdermal patch of rotigotine |
JP2017516768A (ja) | 2014-05-22 | 2017-06-22 | セラピューティックスエムディー インコーポレーテッドTherapeuticsmd, Inc. | 天然の併用ホルモン補充療法剤及び療法 |
US10328087B2 (en) | 2015-07-23 | 2019-06-25 | Therapeuticsmd, Inc. | Formulations for solubilizing hormones |
KR20180126582A (ko) | 2016-04-01 | 2018-11-27 | 쎄러퓨틱스엠디, 인코퍼레이티드 | 스테로이드 호르몬 약제학적 조성물 |
US10286077B2 (en) | 2016-04-01 | 2019-05-14 | Therapeuticsmd, Inc. | Steroid hormone compositions in medium chain oils |
RU2705896C1 (ru) * | 2019-07-26 | 2019-11-12 | Артем Олегович Бахметьев | Трансдермальный пластырь |
US11633405B2 (en) | 2020-02-07 | 2023-04-25 | Therapeuticsmd, Inc. | Steroid hormone pharmaceutical formulations |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4082881A (en) * | 1976-12-23 | 1978-04-04 | E. R. Squibb & Sons, Inc. | Topical and other type pharmaceutical formulations containing isosorbide carrier |
DE3333240A1 (de) * | 1983-09-12 | 1985-03-28 | Schering AG, 1000 Berlin und 4709 Bergkamen | Mittel zur transdermalen applikation von arzneimittelwirkstoffen |
DE3714140A1 (de) * | 1987-04-28 | 1988-11-10 | Lohmann Therapie Syst Lts | Wirkstoffhaltiges pflaster zur kontrollierten verabreichung von wirkstoffen an die haut, seine verwendung sowie verfahren zur gesteuerten verabreichung von wirkstoffen an die haut |
US5538736A (en) * | 1987-04-28 | 1996-07-23 | Lts Lohmann Therapie-Systeme Gmbh | Active substance-containing plaster for the controlled administration of active substances to the skin |
IT1223343B (it) * | 1987-11-03 | 1990-09-19 | Also Lab Sas | Formulazioni farmaceutiche per somministrazione transdermica |
DE3933460A1 (de) * | 1989-10-06 | 1991-04-18 | Lohmann Therapie Syst Lts | Oestrogenhaltiges wirkstoffpflaster |
DE59004243D1 (de) * | 1990-06-14 | 1994-02-24 | Henning Berlin Gmbh | Flüssig befüllte Steckkapselpräparate. |
-
1994
- 1994-02-18 DE DE4405898A patent/DE4405898A1/de not_active Withdrawn
-
1995
- 1995-02-09 AT AT95908925T patent/ATE186213T1/de not_active IP Right Cessation
- 1995-02-09 HU HU9602283A patent/HUT74876A/hu unknown
- 1995-02-09 PT PT95908925T patent/PT744944E/pt unknown
- 1995-02-09 DK DK95908925T patent/DK0744944T3/da active
- 1995-02-09 KR KR1019960704501A patent/KR100392435B1/ko not_active IP Right Cessation
- 1995-02-09 US US08/693,050 patent/US5904931A/en not_active Expired - Fee Related
- 1995-02-09 DE DE59507188T patent/DE59507188D1/de not_active Expired - Fee Related
- 1995-02-09 RU RU96118462/14A patent/RU2154455C2/ru not_active IP Right Cessation
- 1995-02-09 WO PCT/EP1995/000483 patent/WO1995022322A1/de active IP Right Grant
- 1995-02-09 AU AU17066/95A patent/AU1706695A/en not_active Abandoned
- 1995-02-09 NZ NZ279820A patent/NZ279820A/en not_active IP Right Cessation
- 1995-02-09 CA CA002183543A patent/CA2183543C/en not_active Expired - Fee Related
- 1995-02-09 JP JP7521561A patent/JPH09508912A/ja active Pending
- 1995-02-09 EP EP95908925A patent/EP0744944B1/de not_active Expired - Lifetime
- 1995-02-09 ES ES95908925T patent/ES2140658T3/es not_active Expired - Lifetime
-
1996
- 1996-08-19 NO NO19963447A patent/NO313813B1/no not_active IP Right Cessation
-
2000
- 2000-01-28 GR GR20000400206T patent/GR3032512T3/el not_active IP Right Cessation
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002536403A (ja) * | 1999-02-10 | 2002-10-29 | イエナフアルム ゲーエムベーハー ウント ツェーオー. カーゲー | 経皮系のための作用物質含有ラミネート |
JP2004525872A (ja) * | 2000-12-21 | 2004-08-26 | シエーリング アクチエンゲゼルシャフト | 強力なゲスターゲンを含有する経皮系 |
JP2012533598A (ja) * | 2009-07-21 | 2012-12-27 | ノバルティス アーゲー | 医薬組成物 |
JP2015199753A (ja) * | 2009-07-21 | 2015-11-12 | ノバルティス アーゲー | 医薬組成物 |
JP2018199701A (ja) * | 2011-05-15 | 2018-12-20 | エーセラス ファーマシューティカルズ コーポレーション | 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用 |
JP2020079257A (ja) * | 2011-05-15 | 2020-05-28 | エーセラス バイオファーマ インコーポレイテッド | 鼻腔内テストステロン生体付着性ゲル製剤および男性の性腺機能低下症の治療のためのその使用 |
Also Published As
Publication number | Publication date |
---|---|
WO1995022322A1 (de) | 1995-08-24 |
EP0744944A1 (de) | 1996-12-04 |
CA2183543A1 (en) | 1995-08-24 |
KR970701039A (ko) | 1997-03-17 |
ES2140658T3 (es) | 2000-03-01 |
PT744944E (pt) | 2000-04-28 |
CA2183543C (en) | 2009-07-14 |
DE59507188D1 (de) | 1999-12-09 |
HUT74876A (en) | 1997-02-28 |
RU2154455C2 (ru) | 2000-08-20 |
HU9602283D0 (en) | 1996-10-28 |
US5904931A (en) | 1999-05-18 |
DK0744944T3 (da) | 2000-04-25 |
AU1706695A (en) | 1995-09-04 |
NO313813B1 (no) | 2002-12-09 |
EP0744944B1 (de) | 1999-11-03 |
KR100392435B1 (ko) | 2003-11-28 |
ATE186213T1 (de) | 1999-11-15 |
NZ279820A (en) | 1998-08-26 |
NO963447L (no) | 1996-08-19 |
GR3032512T3 (en) | 2000-05-31 |
DE4405898A1 (de) | 1995-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH09508912A (ja) | 性ステロイドを含有する経皮治療系 | |
US5788984A (en) | Gestodene-containing agent for transdermal administration | |
US5145682A (en) | Transdermal absorption dosage unit for postmenopausal syndrome treatment and process for administration | |
AU687013B2 (en) | Transdermal application agent containing 3-keto-desogestrel | |
CN101940790B (zh) | 一种新型促渗剂组合物及其在透皮给药系统中的应用 | |
JP2014051507A (ja) | 避妊及びホルモン補充のためのノルエルゲストロミンを含む経皮治療システム | |
JPH04504109A (ja) | エストロゲン/プロゲスチン経皮投与ユニット,そのシステムとプロセス | |
SK280631B6 (sk) | Systém na simultánnu transdermálnu aplikáciu nieko | |
JPH09508911A (ja) | デソゲストレルを含有する経皮適用剤 | |
TW474826B (en) | New devices intended for the transdermic administration of trimegestone, their preparation process and their use as medicaments | |
JPH11509222A (ja) | 13−エチル−17β−ヒドロキシ−11−メチレン−18,19−ジノル−17α−プレグン−4−エン−20−イン−3−オンのエステルを含む経皮投与のための剤 | |
PL162400B1 (pl) | Sposób wytwarzania poprzezskórnego ukladu terapeutycznego PL | |
AU724308B2 (en) | Transdermal therapeutic systems that contain sex steroids | |
JPH07101864A (ja) | 経皮吸収貼付剤 | |
KR100496109B1 (ko) | 개별격실에2종의활성성분을함유하는경피시스템,그의제조방법및의약으로서의그의용도 | |
JPH09510697A (ja) | 14α,17α−エタノエストラ−1,3,5(10)−トリエン−3,17β−ジオールを含有する経皮投与のための薬剤 | |
SI9300687A (en) | Transdermal hormone replacement therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050913 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20051209 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060310 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070814 |